Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial

Eric G. Meissner, Mary McLaughlin, Lindsay Matthews, Ahmed M. Gharib, Bradford J. Wood, Elliot Levy, Ralph Sinkus, Kimmo Virtaneva, Dan Sturdevant, Craig Martens, Stephen F. Porcella, Zachary D. Goodman, Bittoo Kanwar, Robert P. Myers, Mani Subramanian, Colleen Hadigan, Henry Masur, David E. Kleiner, Theo Heller, Shyam KottililJoseph A. Kovacs, Caryn G. Morse*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

74 Citations (Scopus)

Abstract

Drugs that reverse liver fibrosis are currently getting developed. Non-invasive quantification of the fibrosis degree is key to monitor therapy. This clinical trial for a novel drug was conducted at NIH. MR-Elastography was used as imaging biomarker to verify whether success of therapy can be monitored via biomechanics. MRE showed that the drug had no effect which was confirmed by histopathology. While for the drug company a deception, for MRE this was a success since it is more difficult to "see nothing when there is nothing". This paper convinced a major MRI constructor to translate our technology into a product.
Original languageEnglish
Pages (from-to)1783-1792
Number of pages10
JournalLIVER INTERNATIONAL
Volume36
Issue number12
Early online date27 May 2016
DOIs
Publication statusPublished - 1 Dec 2016

Keywords

  • hepatic venous pressure gradient
  • lysyl oxidases
  • magnetic resonance elastography
  • transforming growth factor beta-3

Fingerprint

Dive into the research topics of 'Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial'. Together they form a unique fingerprint.

Cite this